Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.10 ▼ -0.54
(-6.25%)
MKT CAP: $542.3M • VOL: 150.6K
52W L $7 52W H $16
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$7
MEDIAN
$9
MEAN
$9
HIGH
$11
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ETRA TAPE
ETRA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $9.80 | $9.31 | 2025-02-14 | $7.37 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $10.21 | $9.56 | 2025-02-06 | $7.61 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $9.23 | $8.91 | 2025-01-29 | $7.78 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $8.26 | — | 2025-01-17 | $7.94 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $7.13 | $7.69 | 2025-01-09 | $7.21 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $9.64 | $8.42 | 2024-12-18 | $7.05 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $7.86 | $8.18 | 2024-12-04 | $7.53 | -4.3% | 48% | C |